Influence of particle size on the in vitro and in vivo anti-inflammatory and anti-Allergic activities of a curcumin lipid nanoemulsion

International Journal of Molecular Medicine

Volumn 35, Issue 6, 2015, Pages 1720-1728

  Onodera, Takefumi ^a   Kuriyama, Isoko ^a   Andoh, Tooru ^a   Ichikawa, Hideki ^a   Sakamoto, Yuka ^a   Lee Hiraiwa, Eibai ^a   Mizushina, Yoshiyuki ^a,b  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

Author keywords

Anti Allergic; Anti inflammatory; Curcumin; Lipid nanoemulsion; Tumor necrosis factor ; hexosaminidase

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; CALCIMYCIN; CURCUMIN; IMMUNOGLOBULIN E; LIPID; LIPOPOLYSACCHARIDE; PHORBOL 13 ACETATE 12 MYRISTATE; SOYBEAN OIL; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; DRUG CARRIER; EMULSION; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DEGRANULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; EAR EDEMA; ENZYME INHIBITION; HYDRATION; MALE; MOUSE; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PASSIVE SKIN ANAPHYLAXIS; PRIORITY JOURNAL; RAT; ULTRASOUND; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; EDEMA; EMULSION; INSTITUTE FOR CANCER RESEARCH MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CURCUMIN; DRUG CARRIERS; EDEMA; EMULSIONS; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; NANOPARTICLES; PARTICLE SIZE; RATS; TETRADECANOYLPHORBOL ACETATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928392364     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2186     Document Type: Article

References (52)

1. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm 4: 807-818, 2007
2. Ammon HP, Safayhi H, Mack T and Sabieraj J: Mechanism of antiinflammatory actions of curcumine and boswellic acids. J Ethnopharmacol 38: 113-119, 1993
3. Banerjee A and Nigam SS: Antimicrobial efficacy of the essential oil of Curcuma longa. Indian J Med Res 68: 864-866, 1978
4. Bhavani Shankar TN and Sreenivasa Murthy V: Effect of turmeric (Curcuma longa) fractions on the growth of some intestinal and pathogenic bacteria in vitro. Indian J Exp Biol 17: 1363-1366, 1979
5. Sawada T, Yamahara J, Shimazu S and Ohta T: Evaluation of crude drugs by bioassay. III. Comparison with local variation of contents and the fungistatic action of essential oil from the root of Curcuma longa. Shoyakugaku Zasshi 25: 11-16, 1971
6. Rao DS, Sekhara NC, Satyanarayana MN and Srinivasan M: Effect of curcumin on serum and liver cholesterol levels in the rat. J Nutr 100: 1307-1315, 1970
7. Limtrakul P, Anuchapreeda S, Lipigorngoson S and Dunn FW: Inhibition of carcinogen induced c-Ha-ras and c-fos proto-oncogenes expression by dietary curcumin. BMC Cancer 1: 1-7, 2001
8. Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S and Chanarat P: Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res 29: 80-87, 2006
9. Anuchapreeda S, Thanarattanakorn P, Sittipreechacharn S, Chanarat P and Limtrakul P: Curcumin inhibits WT1 gene expression in human leukemic K562 cells. Acta Pharmacol Sin 27: 360-366, 2006
10. Anuchapreeda S, Tima S, Duangrat C and Limtrakul P: Effect of pure curcumin, demethoxycurcumin, and bisdemethoxycurcumin on WT1 gene expression in leukemic cell lines. Cancer Chemother Pharmacol 62: 585-594, 2008
11. Polasa K, Raghuram TC, Krishna TP and Krishnaswamy K: Effect of turmeric on urinary mutagens in smokers. Mutagenesis 7: 107-109, 1992
12. Roy RG, Madesayaa NM, Ghosh RB, Gopalakrishnan DV, Murthy NN, Dorairaj TJ and Sitaraman NL: Study on inhalation therapy by an indigenous compound on P. vivax and P. falciparum infections-A preliminary communication. Indian J Med Res 64: 1451-1455, 1976
13. Azuine MA and Bhide SV: Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. Nutr Cancer 17: 77-83, 1992
14. Dorai T, Cao YC, Dorai B, Buttyan R and Katz AE: Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate 47: 293-303, 2001
15. Anuchapreeda S, Muangmoonchai R and Limtrakul P: Effect of curcuminoids on MDR1 gene promoter activity in human cervical carcinoma cells. Chiang Mai Med Bull 41: 189-202, 2002
16. Mizushina Y, Hirota M, Murakami C, Ishidoh T, Kamisuki S, Shimazaki N, Takemura M, Perpelescu M, Suzuki M, Yoshida H, et al: Some anti-chronic inflammatory compounds are DNA polymerase λ-specific inhibitors. Biochem Pharmacol 66: 1935-1944, 2003
17. Takeuchi T, Ishidoh T, Iijima H, Kuriyama I, Shimazaki N, Koiwai O, Kuramochi K, Kobayashi S, Sugawara F, Sakaguchi K, et al: Structural relationship of curcumin derivatives binding to the BRCT domain of human DNA polymerase λ. Genes Cells 11: 223-235, 2006
18. kB activation. Int J Mol Med 25: 761-767, 2010
19. Mizushina Y, Nishida M, Azuma T and Yoshida M: Inhibition of DNA polymerase λ, a DNA repair enzyme, and anti-inflammation: chemical knocked out analysis for DNA polymerase λ using curcumin derivatives. DNA Repair and Human Health. Chapter 31. InTech. Vengrova S (ed), pp777-792, 2011
20. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21: 2895-2900, 2001
21. Garcea G, Berry DP, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP and Gescher AJ: Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14: 120-125, 2005
22. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, et al: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68: 157-164, 2011
23. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-6854, 2004
24. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z and Brenner DE: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17: 1411-1417, 2008
25. Porter CJ, Trevaskis NL and Charman WN: Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6: 231-248, 2007
26. Solans C, Izquierdo P, Nolla J, Azemar N and Garcia-Celma MJ: Nanoemulsions. Curr Opin Colloid Interface Sci 10: 102-110, 2005
27. Wheeler JJ, Wong KF, Ansell SM, Masin D and Bally MB: Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci 83: 1558-1564, 1994
28. Liu F and Liu D: Long-circulating emulsions (oil-in-water) as carriers for lipophilic drugs. Pharm Res 12: 1060-1064, 1995
29. Kurihara A, Shibayama Y, Mizota A, Yasuno A, Ikeda M, Sasagawa K, Kobayashi T and Hisaoka M: Lipid emulsions of palmitoylrhizoxin: Effects of composition on lipolysis and biodistribution. Biopharm Drug Dispos 17: 331-342, 1996
30. Wang Y, Mesfin GM, Rodríguez CA, Slatter JG, Schuette MR, Cory AL and Higgins MJ: Venous irritation, pharmacokinetics, and tissue distribution of tirilazad in rats following intravenous administration of a novel supersaturated submicron lipid emulsion. Pharm Res 16: 930-938, 1999
31. Maranhão RC, Garicochea B, Silva EL, Dorlhiac-Llacer P, Cadena SM, Coelho IJ, Meneghetti JC, Pileggi FJ and Chamone DA: Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 54: 4660-4666, 1994
32. Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y and Tokuuye K: Preparation of gadolinium-containing emulsions stabilized with phosphatidylcholine-surfactant mixtures for neutron-capture therapy. Chem Pharm Bull (Tokyo) 47: 203-208, 1999
33. Miyamoto M, Hirano K, Ichikawa H, Fukumori Y, Akine Y and Tokuuye K: Biodistribution of gadolinium incorporated in lipid emulsions intraperitoneally administered for neutron-capture therapy with tumor-bearing hamsters. Biol Pharm Bull 22: 1331-1340, 1999
34. Razin E, Mencia-Huerta JM, Stevens RL, Lewis RA, Liu FT, Corey E and Austen KF: IgE-mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, β-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells. J Exp Med 157: 189-201, 1983
35. Sato H, Kobayashi Y, Hattori A, Suzuki T, Shigekawa M and Jippo T: Inhibitory effects of water-soluble low-molecular-weight β-(1,3-1,6) D-glucan isolated from Aureobasidium pullulans 1A1 strain black yeast on mast cell degranulation and passive cutaneous anaphylaxis. Biosci Biotechnol Biochem 76: 84-88, 2012
36. Soler-Rodriguez AM, Zhang H, Lichenstein HS, Qureshi N, Niesel DW, Crowe SE, Peterson JW and Klimpel GR: Neutrophil activation by bacterial lipoprotein versus lipopolysaccharide: differential requirements for serum and CD14. J Immunol 164: 2674-2683, 2000
37. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T and Matsushima K: Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 96: 2584-2591, 2000
38. Aggarwal BB: Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 3: 745-756, 2003
39. Supajatura V, Ushio H, Nakao A, Akira S, Okumura K, Chisei R and Ogawa H: Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest 109: 1351-1359, 2002
40. Metcalfe DD, Peavy RD and Gilfillan AM: Mechanisms of mast cell signaling in anaphylaxis. J Allergy Clin Immunol, 124: 639-646, 2009
41. Payton F, Sandusky P and Alworth WL: NMR study of the solution structure of curcumin. J Nat Prod 70: 143-146, 2007
42. Li L, Braiteh FS and Kurzrock R: Liposome-encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer 104: 1322-1331, 2005
43. Maiti K, Mukherjee K, Gantait A, Saha BP and Mukherjee PK: Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330: 155-163, 2007
44. Mizushina Y, Maeda N, Kawasaki M, Ichikawa H, Murakami C, Takemura M, Xu X, Sugawara F, Fukumori Y, Yoshida H, et al: Inhibitory action of emulsified sulfoquinovosyl acylglycerol on mammalian DNA polymerases. Lipids 38: 1065-1074, 2003
45. Anuchapreeda S, Fukumori Y, Okonogi S and Ichikawa H: Preparation of lipid nanoemulsions incorporating curcumin for cancer therapy. J Nanotechnol Article 2012: 270383, 2012
46. Hung CF, Hwang TL, Chang CC and Fang JY: Physicochemical characterization and gene transfection efficiency of lipid emulsions with various co-emulsifiers. Int J Pharm 289: 197-208, 2005
47. Chinsriwongkul A, Opanasopit P, Ngawhirunpat T, Chareansriwilaiwat N, Sila-On W and Ruktanonchai U: Physicochemical properties of lipid emulsions formulated with high-load all-trans-retinoic acid. PDA J Pharm Sci Technol 61: 461-471, 2007
48. Texier I, Goutayer M, Da Silva A, Guyon L and Djaker N: Cyanine-loaded lipid nanoparticles for improved in vivo fluorescence imaging. J Biomed Opt 14: 054005, 2009
49. Goutayer M, Dufort S, Josserand V, Royere A, Heinrich E, Vinet F, Bibette J, Coll JL and Texier I: Tumor targeting of functionalized lipid nanoparticles: assessment by in vivo fluorescence imaging. Eur J Pharm Biopharm 75: 137-147, 2010
50. Hurstand WJ and Martin RA Jr: The analysis of phospholipids in soy lecithin by HPLC. J Am Oil Chem Soc 61: 1462-1463, 1984
51. Sonneville-Aubrun O, Simonnet JT and L'Alloret F: Nanoemulsions: A new vehicle for skincare products. Adv Colloid Interface Sci 108-109: 145-149, 2004
52. Patel D and Sawant KK: Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev Ind Pharm 33: 1318-1326, 2007.